• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: Director Akkaraju Srinivas bought $25,000,000 worth of shares (1,562,500 units at $16.00) (SEC Form 4)

    8/27/24 4:10:05 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALMS alert in real time by email
    SEC FORM 4/A SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    AKKARAJU SRINIVAS

    (Last) (First) (Middle)
    C/O ALUMIS INC.
    280 EAST GRAND AVENUE

    (Street)
    SOUTH SAN FRANCISCO CA 94080

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    ALUMIS INC. [ ALMS ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    07/01/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    07/01/2024
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 07/01/2024(1) P 1,562,500 A $16 3,266,498 I By Samsara BioCapital, L.P.(2)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. The original Form 4 inadvertently omitted the purchase of shares by Samsara in the Issuer's initial public offering.
    2. Shares are held directly by Samsara BioCapital, L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara GP") is the general partner of Samsara LP. The Reporting Person, as the managing member of Samsara GP, shares voting and investment authority over the shares held by Samsara LP. The Reporting Person disclaims beneficial ownership in these shares except to the extent of his pecuniary interest therein.
    /s/ Srinivas Akkaraju 08/27/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ALMS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALMS

    DatePrice TargetRatingAnalyst
    6/10/2025$18.00Buy
    Guggenheim
    1/30/2025$32.00Outperform
    Oppenheimer
    10/31/2024$25.00Outperform
    Robert W. Baird
    10/17/2024$30.00Buy
    H.C. Wainwright
    7/23/2024Overweight
    Cantor Fitzgerald
    7/23/2024$29.00Outperform
    Leerink Partners
    7/23/2024$32.00Buy
    Guggenheim
    7/23/2024$36.00Overweight
    Morgan Stanley
    More analyst ratings

    $ALMS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Alumis to Present at the Jefferies Global Healthcare Investor Conference

      SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that Martin Babler, President and Chief Executive Officer of Alumis, will present at the Jefferies Global Healthcare Conference on June 4, 2025 at 3:10 p.m. ET. A live webcast will be available on the Alumis website in the "Investors" section under the "Events" page. A replay of the conference webcast will be archived on the company's website for 90 days. About Alumis Alumis is a late-stage biopharma company developing next-generation targeted therapies with the pot

      5/29/25 4:15:56 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis

      SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the completion of patient enrollment in its pivotal Phase 3 ONWARD clinical program of ESK-001 for the treatment of moderate-to-severe plaque psoriasis. "We are excited to announce the completion of patient enrollment in our pivotal Phase 3 ONWARD clinical program evaluating ESK-001 for moderate-to-severe plaque psoriasis," said Martin Babler, President and Chief Executive Officer of Alumis. "With over 1,700 patients enrolled across the two trials, this milestone ref

      5/29/25 7:55:00 AM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alumis Completes Merger with ACELYRIN

      SOUTH SAN FRANCISCO, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that it has completed its merger with ACELYRIN, Inc. Each ACELYRIN stockholder will receive 0.4814 shares of Alumis common stock for each share of ACELYRIN common stock owned. ACELYRIN common stock has ceased trading and will no longer be listed on the NASDAQ Global Select Market. "We are excited to complete our merger and move forward with a significantly strengthened balance sheet to support Alumis' differentiated late-stage portfolio and develop transformative th

      5/21/25 9:10:51 AM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALMS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Guggenheim resumed coverage on Alumis with a new price target

      Guggenheim resumed coverage of Alumis with a rating of Buy and set a new price target of $18.00

      6/10/25 8:07:01 AM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Alumis with a new price target

      Oppenheimer initiated coverage of Alumis with a rating of Outperform and set a new price target of $32.00

      1/30/25 7:47:22 AM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Robert W. Baird initiated coverage on Alumis with a new price target

      Robert W. Baird initiated coverage of Alumis with a rating of Outperform and set a new price target of $25.00

      10/31/24 6:14:08 AM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALMS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Tananbaum James B. bought $202,300 worth of shares (45,000 units at $4.50) (SEC Form 4)

      4 - ALUMIS INC. (0001847367) (Issuer)

      5/6/25 9:48:59 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Foresite Labs, Llc bought $202,300 worth of shares (45,000 units at $4.50) (SEC Form 4)

      4 - ALUMIS INC. (0001847367) (Issuer)

      5/6/25 9:48:12 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Foresite Capital Management Vi Llc bought $202,300 worth of shares (45,000 units at $4.50) (SEC Form 4)

      4 - ALUMIS INC. (0001847367) (Issuer)

      5/6/25 9:47:18 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALMS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $ALMS
    SEC Filings

    See more

    $ALMS
    Financials

    Live finance-specific insights

    See more

    $ALMS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Director Akkaraju Srinivas was granted 1,214,582 shares (SEC Form 4)

      4 - ALUMIS INC. (0001847367) (Issuer)

      5/23/25 8:47:53 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ayurmaya Capital Management Company, Lp was granted 4,493,741 shares (SEC Form 4)

      4 - ALUMIS INC. (0001847367) (Issuer)

      5/23/25 4:20:51 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Machado Patrick was granted 7,064 shares (SEC Form 4)

      4 - ALUMIS INC. (0001847367) (Issuer)

      5/23/25 4:05:20 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Alumis Inc.

      S-8 - ALUMIS INC. (0001847367) (Filer)

      6/10/25 4:46:36 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Alumis Inc.

      SCHEDULE 13D/A - ALUMIS INC. (0001847367) (Subject)

      5/23/25 8:49:18 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Alumis Inc.

      SCHEDULE 13D/A - ALUMIS INC. (0001847367) (Subject)

      5/23/25 4:16:27 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

      Topline data from Phase 3 ONWARD trials for Alumis' ESK-001 in moderate-to-severe plaque psoriasis on track for readout in first half of 2026; Topline data from Phase 2b LUMUS trial in systemic lupus erythematosus on track for readout in 2026 Evaluation underway of development plan for ACELYRIN's lonigutamab to confirm differentiation in a capital efficient manner Pro forma cash position of approximately $737 million as of December 31, 2024, provides runway into 2027, beyond expected multiple clinical readouts for highly differentiated late-stage portfolio Alumis and ACELYRIN stockholders to own ~55% and ~45%, respectively, of combined company on a fully diluted basis Combined company wi

      2/6/25 4:15:00 PM ET
      $ALMS
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Alumis Inc.

      SC 13D - ALUMIS INC. (0001847367) (Subject)

      8/27/24 4:20:38 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Alumis Inc.

      SC 13G - ALUMIS INC. (0001847367) (Subject)

      7/11/24 4:30:21 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Alumis Inc.

      SC 13D - ALUMIS INC. (0001847367) (Subject)

      7/5/24 9:30:17 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care